Why Investors are Pushing Into Psychedelic Stocks

Psilocybin has made major headlines over the last few days.

Not only was it legalized in Oregon and Washington, D.C., a new study shows its useful in treating depressive disorders.

In fact, a study from JAMA Psychiatry just found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.  In addition, researchers are finding the psychedelic may also help with anxiety, PTSD, opioid addictions, obsessive-compulsive disorder (OCD), and alcoholism.

It may even be useful in treating eating disorders and obesity.  That’s because psilocybin activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.”